Multi-partner grant awarded for the validation of Genedrive® CYP2C19 ID Kit in time-critical NHS settings
Genedrive PLC – NICE recommends CYP2C19 genotyping
Genedrive plc (AIM: GDR), a leading provider of point-of-care molecular diagnostics, has announced that the UK’s National Institute for Health and Care Excellence (NICE) is advising in a draft guideline
Genedrive PLC (AIM:GDR) Commence of roll out in Greater Manchester
Genedrive ® MT-RNR1 to commence roll out in Greater Manchester Project to follow NICE final recomendations scheduled for end of this month
Genedrive PLC (AIM:GDR) AIHL test preliminary recommendation by NICE
Antibiotic Induced Hearing Loss test receives preliminary recommendation by NICE NICE enters public consultation phase of Early Value Assessment of the Genedrive® MT-RNR1 System
Flybe’s collapse: Can I get a refund or will I be offered a different flight?
Flybe’s airline has crashed for the second time within three years. This cancelled all flights and caused disruption for thousands of passengers.
Braveheart Inv Group (AIM:BRH) Operational update
Braveheart Investment Group plc (AIM: BRH) provides the following update on Phasefocus and Paraytec, companies within the Group’s investment portfolio.
As Border Force, postal and railway staff walk out before Christmas, strike misery is imminent
Walkouts are planned for the days leading up to Christmas.
As the Cold Snap continues, Snow moves into parts of UK
As forecasters warn about severe weather conditions, snow has been spotted in parts of the UK.
Genedrive PLC (AIM:GDR) US FDA pre-submission for Genedrive MT-RNR1 kit
Genedrive file US FDA Pre-Submission for the Genedrive ® MT-RNR1 Product Range
Fury over ‘criminal’ energy prices as a pub reveals £61k bill from British Gas
The UK’s night time tsar has warned that pubs and restaurants will face “criminal” energy costs and that Britain should be prepared for record numbers of closures.
Genedrive PLC (AIM:GDR) NICE includes Genedrive CYP2C19-ID Kit in new Diagnostics Assessment Programme
genedrive plc (AIM: GDR), the near-patient molecular diagnostics company, announces that the UK’s National Institute for Health and Clinical Excellence (‘NICE’) has commenced an evaluation of CYP2C19 genotype testing for